HUTCHMED (China) Limited (HCM)
Healthcare • Drug Manufacturers - Specialty & Generic
StockNasdaqGSHong KongUS44842L1035
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by HUTCHMED (China) Limited, and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 13 Nov 2026 14:51. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 04 Mar 2027 08:00 | — | — | — | Upcoming |
| 02 Mar 2022 19:00 | -0.13 | -0.03 | +77.5% | Beat |
| 28 Jul 2021 07:00 | -0.07 | -0.40 | -477.9% | Miss |
| 21 Jun 2021 07:00 | -0.37 | -0.30 | +18.9% | Beat |
| 20 Jun 2021 20:00 | -0.18 | -0.01 | +94.4% | Beat |
| 04 Mar 2021 09:00 | -0.13 | -0.03 | +77.5% | Beat |
| 30 Jul 2020 08:00 | -0.18 | -0.03 | +83.3% | Beat |
| 03 Mar 2020 07:00 | -0.23 | -0.25 | -8.7% | Miss |
| 02 Mar 2020 19:00 | — | -0.01 | — | — |
| 21 Jan 2020 16:00 | -0.31 | -0.20 | +35.5% | Beat |
| 30 Jul 2019 04:00 | -0.14 | -0.04 | +71.3% | Beat |
| 06 Jun 2019 06:00 | -0.13 | -0.03 | +76.9% | Beat |
| 10 Mar 2019 20:00 | -0.01 | -0.01 | +200.0% | Beat |
| 27 Jul 2018 02:00 | -0.07 | -0.47 | -571.4% | Miss |
| 26 Jul 2018 20:00 | — | — | — | — |
| 11 Mar 2018 20:00 | — | 0.01 | — | — |
| 31 Jul 2017 13:00 | 0.07 | 0.01 | -85.7% | Miss |
| 30 Jul 2017 20:00 | 0.13 | — | -100.0% | — |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 548.5M | -13.0% | 456.9M | 83.3% | 2.65 | +1,225.0% | -88.8M |
| 2024 | 630.2M | -24.8% | 37.7M | 6.0% | 0.20 | -66.7% | -17.4M |
| 2023 | 838M | +96.5% | 100.8M | 12.0% | 0.60 | +127.9% | 186.6M |
| 2022 | 426.4M | — | -360.8M | -84.6% | -2.15 | — | -305.3M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 09 Nov 2026 – 13 Nov 2026 In progress | 15.29 | 15.48 | 14.81 | 14.94 | -1.45% | 131,951 | |
| 02 Nov 2026 – 06 Nov 2026 | 13.23 | 15.31 | 13.02 | 15.16 | +15.29% | 428,900 | |
| 26 Oct 2026 – 30 Oct 2026 | 14.34 | 14.42 | 13.12 | 13.15 | -8.43% | 175,400 | |
| 19 Oct 2026 – 23 Oct 2026 | 14.08 | 14.94 | 14.01 | 14.36 | +2.21% | 198,500 | |
| 12 Oct 2026 – 16 Oct 2026 | 14.00 | 14.28 | 13.28 | 14.05 | -0.35% | 236,900 | |
| 05 Oct 2026 – 09 Oct 2026 | 14.14 | 14.75 | 13.51 | 14.10 | -0.70% | 286,800 | |
| 28 Sep 2026 – 02 Oct 2026 | 13.93 | 14.93 | 13.93 | 14.20 | +1.87% | 270,700 | |
| 21 Sep 2026 – 25 Sep 2026 | 14.06 | 14.55 | 13.81 | 13.94 | +1.98% | 383,800 | |
| 14 Sep 2026 – 18 Sep 2026 | 13.35 | 13.89 | 13.35 | 13.67 | +6.63% | 265,500 | |
| 08 Sep 2026 – 11 Sep 2026 | 14.00 | 14.05 | 12.79 | 12.82 | -9.01% | 332,000 | |
| 252 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- HUTCHMED (China) Limited (HCM) Presents at Deutsche Bank Virtual Investor Conference Transcript (opens in a new tab) SeekingAlpha · 12 Nov 2026 11:58
- Should Phase III Lung Cancer Data Require Action From Hutchmed (AIM:HCM) Investors? (opens in a new tab) Simply Wall St. · 08 Nov 2026 09:11
- HUTCHMED (China) (AIM:HCM) Extends Lung Cancer Filing Run As Undervalued View Holds (opens in a new tab) Simply Wall St. · 06 Nov 2026 01:21
- Reported Earlier, HUTCHMED’s Oral Syk Inhibitor Sovleplenib Gets US FDA Orphan Drug Designation For Autoimmune Hemolytic Anemia, Its Second After Primary ITP, Eligible For 7 Years Of US Market Exclusivity Upon Approval (opens in a new tab) Benzinga · 05 Nov 2026 03:13
- HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Autoimmune Hemolytic Anemia (opens in a new tab) 05 Nov 2026 00:00
- HUTCHMED (AIM:HCM) Stock May Look Rich As FDA Orphan Drug News Lands (opens in a new tab) Simply Wall St. · 03 Nov 2026 00:21
- What HUTCHMED (China) (AIM:HCM)'s GSK Licensing Deal Means For Shareholders (opens in a new tab) Simply Wall St. · 25 Oct 2026 07:12
- HUTCHMED (China) (AIM:HCM) Closes GSK Deal, Is The Stock Still 38% Undervalued? (opens in a new tab) Simply Wall St. · 23 Oct 2026 01:19
- HUTCHMED (AIM:HCM) Stock Looks Expensive Relative To Current Earnings (opens in a new tab) Simply Wall St. · 18 Oct 2026 05:17
- How Investors May Respond To HUTCHMED (China) (AIM:HCM) US NDA For ORPATHYS–TAGRISSO Lung Cancer Combo (opens in a new tab) Simply Wall St. · 13 Oct 2026 04:16
- GSK Bets on HUTCHMED to Expand its Multi-Billion-Dollar Oncology Opportunity (opens in a new tab) Insider Monkey · 24 Sep 2026 21:59
- HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy (opens in a new tab) MarketBeat · 03 Sep 2026 18:02
- Panmure and Cavendish reiterate buy on Hutchmed after GSK deal (opens in a new tab) Proactive · 03 Sep 2026 10:30
- HUTCHMED shares jump 17% on US$1.3 billion GSK cancer drug deal (opens in a new tab) Proactive · 03 Sep 2026 08:27
- HUTCHMED shares rise as lung cancer drug trial hits key targets (opens in a new tab) Proactive · 17 Aug 2026 15:37
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 14.85 USD
- Market cap
- 2.6B
- Exchange
- NasdaqGS
- Country
- Hong Kong
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 14.6 / 25 |
|
| Quality Return on equity, net margin and how stable the margins are. | 0.2 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 3.8 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 0.0 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 10.0 / 10 |
|
- Score capped at 50: three or more warnings
- Thin interest cover: operating profit is only -12.5× the interest
- Total debt has risen three years in a row
- Revenue has fallen two years in a row
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A). Warnings take 18 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio. How the score works
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (trailing) | 148.5× | Weak | 30.56× |
| P/E (forward) | 57.29× | Weak | 14.16× |
| Price / book | 2.05× | Fair | 3.5× |
| Price / sales | 4.7× | Fair | 3.33× |
| EV / EBITDA | -65.97× | Weak | 11.19× |
| Free cash flow yield | -0.7% | Weak | 2.1% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 13.3% | Weak | 54.9% |
| Operating margin | -6.3% | Weak | 5.8% |
| Net margin | 3.3% | Weak | 1.2% |
| Return on equity | 1.5% | Weak | 4.4% |
| Return on assets | -1.2% | Weak | 2.7% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | 8.8% | Good | 10.1% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 0.07× | Good | 0.4× |
| Interest cover | -12.46× | Weak | 2.17× |
| Current ratio | 5.64× | Good | 2.64× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 0% | Weak | 0% |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Similar shares
Follow HCM and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.